GU Cancers 2021 | The history of biomarkers in the treatment of prostate cancer

Howard Scher, MD, FASCO, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses biomarkers associated with poor outcome in prostate cancer at ASCO GU 2021. Dr Scher outlines challenges in response monitoring associated with bone metastases. Current response measures include changes in prostate-specific antigen (PSA). Dr Scher gives an overview of how circulating tumor cells (CTCs), which are present in blood, offer a novel biomarker for response monitoring in prostate cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.